Sponsors

Company Profile

Mithridion, Inc

Drug Development
Neurology

505 Science Drive
Suite C
Madison, WI 53711
USA
www.mithridion.com 		Incorporated in 2004
8 Employees 		Privately Held

This Year's Highlights

  • Raised $994,000 in angel capital towards target of $1.8m
  • Awarded NIH SBIR and STTR grants worth $296,800
  • Won Grand Prize, WI Governor's Business Plan Contest 2005

Anticipated Highlights

  • Targeting drug candidate by 2Q-3Q 2007
  • Targeting drug development financing for 3Q 2007

Corporate Mission

Mithridion aims to be one of the first companies to develop effective drugs to slow down or halt disease processes in common neurodegenerative diseases. Mithridion?s initial focus is on meeting the enormous unmet clinical needs of an estimated 4.5m Americans and 12m people worldwide with Alzheimer?s disease (AD), potentially a $10bn market opportunity. Mithridion is developing disease-modifying drugs to slow down or halt the otherwise inexorable and disastrous progress of disease in AD, based on its novel proprietary technology, including advanced small molecule drug leads.